COMP <GO>
ANIK vs CLPT // PIOTROSKI F-SCORE QUALITY
Anika Therapeutics Inc. (NASDAQ) VS. ClearPoint Neuro Inc. (NASDAQ) • 15-METRIC TALLY: ANIK 6
— CLPT 3
▲ PIOTROSKI F-SCORE QUALITY LEADER: ANIK
LAST: $21.79 (+1.11%) • MKT CAP: $291.6M
piotroski-score
6/9
LAST: $10.69 (+1.23%) • MKT CAP: $342.7M
piotroski-score
4/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIK VS. CLPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIK | CLPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.60% | 61.40% | -4.80 | CLPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | -35.00% | +24.80 | ANIK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.50% | -7.13% | +8.63 | ANIK | /fcf-yield <GO> |
| Operating Margin | -9.80% | -60.00% | +50.20 | ANIK | /operating-margins <GO> |
| Net Profit Margin | -9.80% | -60.00% | +50.20 | ANIK | /net-margins <GO> |
| Revenue Growth (YoY) | -5.90% | 17.80% | -23.70 | CLPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 4/9 | +2.00 | ANIK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 48.9 | +4.22 | ANIK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $291.6M | $342.7M | -$51.0M | CLPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIK REV | CLPT REV | ANIK GROSS % | CLPT GROSS % | ANIK FCF | CLPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $112.8M | $37.0M | 56.6% | 61.4% | $4.4M | -$24.4M |
| FY 2024 | $119.9M | $31.4M | 63.4% | 60.9% | -$2.3M | -$9.2M |
| FY 2023 | $120.8M | $24.0M | — | — | -$1.8M | -$13.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIK // BETA —
CLPT // BETA —